Literature DB >> 31034300

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Mark J Levis1, Yi-Bin Chen2, Mehdi Hamadani3, Mary M Horowitz3, Richard J Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31034300      PMCID： PMC6804888          DOI： 10.1200/JCO.19.00321

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors:  Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

2.  Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Authors:  Max Jan; Thomas M Snyder; M Ryan Corces-Zimmerman; Paresh Vyas; Irving L Weissman; Stephen R Quake; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

3.  Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

Authors:  D J Propper; A C McDonald; A Man; P Thavasu; F Balkwill; J P Braybrooke; F Caponigro; P Graf; C Dutreix; R Blackie; S B Kaye; T S Ganesan; D C Talbot; A L Harris; C Twelves
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

5.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

6.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Authors:  Yi-Bin Chen; Shuli Li; Andrew A Lane; Christine Connolly; Candice Del Rio; Betsy Valles; Morgan Curtis; Karen Ballen; Corey Cutler; Bimalangshu R Dey; Areej El-Jawahri; Amir T Fathi; Vincent T Ho; Amy Joyce; Steven McAfee; Michelle Rudek; Trivikram Rajkhowa; Sigitas Verselis; Joseph H Antin; Thomas R Spitzer; Mark Levis; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-17       Impact factor: 5.742

Review 7.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Authors:  Mark Levis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Authors:  Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

9.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

10.  Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

Authors:  S K Metzelder; T Schroeder; M Lübbert; M Ditschkowski; K Götze; S Scholl; R G Meyer; P Dreger; N Basara; M F Fey; H R Salih; A Finck; T Pabst; A Giagounidis; G Kobbe; E Wollmer; J Finke; A Neubauer; A Burchert
Journal:  Eur J Cancer       Date:  2017-10-18       Impact factor: 9.162
View more
  14 in total

1.  Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute.

Authors:  Robert J Soiffer
Journal:  Blood Adv       Date:  2020-07-14

2.  Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste.

Authors:  Bart L Scott
Journal:  Blood Adv       Date:  2020-07-14

3.  The growing landscape of FLT3 inhibition in AML.

Authors:  Catherine C Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.

Authors:  Li Wan; Shuqi Ding; Mimi Xu; Kangkang Lv; Yuanyuan Du; Depei Wu; Mingzhu Xu; Yuejun Liu
Journal:  Int J Hematol       Date:  2022-07-20       Impact factor: 2.319

5.  TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Nico Gagelmann; Christine Wolschke; Evgeny Klyuchnikov; Maximilian Christopeit; Francis Ayuk; Nicolaus Kröger
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 6.  Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.

Authors:  Justin Loke; Hrushikesh Vyas; Charles Craddock
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

7.  A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Authors:  Jonathan A Webster; Meera Yogarajah; Marianna Zahurak; Heather Symons; Amy E Dezern; Ivana Gojo; Gabrielle T Prince; Jillian Morrow; Richard J Jones; B Douglas Smith; Margaret Showel
Journal:  Leuk Lymphoma       Date:  2021-07-21

Review 8.  Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Ali Bazarbachi; Gesine Bug; Frederic Baron; Eolia Brissot; Fabio Ciceri; Iman Abou Dalle; Hartmut Döhner; Jordi Esteve; Yngvar Floisand; Sebastian Giebel; Maria Gilleece; Norbert-Claude Gorin; Elias Jabbour; Mahmoud Aljurf; Hagop Kantarjian; Mohamed Kharfan-Dabaja; Myriam Labopin; Francesco Lanza; Florent Malard; Zinaida Peric; Thomas Prebet; Farhad Ravandi; Annalisa Ruggeri; Jaime Sanz; Christoph Schmid; Roni Shouval; Alexandros Spyridonidis; Jurjen Versluis; Norbert Vey; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

Review 9.  The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.

Authors:  Justin Loke; Ram Malladi; Paul Moss; Charles Craddock
Journal:  Br J Haematol       Date:  2019-12-10       Impact factor: 6.998

10.  Quantitative PCR-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study.

Authors:  Valentina Gambacorta; Riccardo Parolini; Elisabetta Xue; Raffaella Greco; Evelien E Bouwmans; Cristina Toffalori; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Alessandro Ambrosi; Benedetta Mazzi; Wietse Mulder; Consuelo Corti; Jacopo Peccatori; Fabio Ciceri; Luca Vago
Journal:  Haematologica       Date:  2020-09-10       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.